Obstructive Sleep Apnea and Genes Expression (HIP)
Sleep Apnea: Interface Between Basic and Clinical Research
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Juliana C Perry, PhD
- Phone Number: 55-11-8636-9979
- Email: julianaciniperry@gmail.com
Study Contact Backup
- Name: Silverio A Garbuio, Master
- Phone Number: 55-11-8611-9251
- Email: silverio.garbuio@gmail.com
Study Locations
-
-
SP
-
Sao Paulo, SP, Brazil, 04020-060
- Recruiting
- AFIP - Instituto do Sono (Sleep Institute)
-
Contact:
- Juliana C Perry, PhD
- Phone Number: 55-11-8636-9979
- Email: julianaciniperry@gmail.com
-
Contact:
- Silverio A Garbuio, Master
- Phone Number: 55-11-8611-9251
- Email: silverio.garbuio@gmail.com
-
Sub-Investigator:
- Juliana C Perry, PhD
-
Principal Investigator:
- Lia Rita A Bittencourt, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male subjects aged between 30 and 60 years old
- Normal range of laboratory tests complete blood count (CBC), glucose, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (LDL), triglycerides
- Body Mass Index (BMI) < 35kg/m2
Exclusion Criteria:
- Presence of clinical diseases (chronic obstructive pulmonary disease, asthma, interstitial lung diseases, neuromuscular diseases, heart failure, thyroid disease, rheumatologic and psychiatric) and other sleep disorders
- Smoking status
- Participants who had current or historical treatment with CPAP or any other treatment for OSA
- Presence of anatomical obstructive upper airway, tonsil grade III and IV septal deviation and grade III (severe) that may affect the outcome of CPAP
- Alcoholism
- Use of sleep-inducing medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CPAP
CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
|
Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apnea/Hypopnea Index
Time Frame: 6 months after the basal evaluation
|
Polysomnographic date of sleep stages percentages, sleep efficiency, arousals, apnea-hypopnea index, oxyhemoglobin saturation
|
6 months after the basal evaluation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gene expression
Time Frame: 6 months after the basal evaluation
|
A total of 84 genes are evaluated using the Hypoxia Signaling Pathway PCR Array (SA Biosciences, EUA), C-reactive protein (CRP), and biochemical parameters
|
6 months after the basal evaluation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Juliana C Perry, PhD, Federal University of São Paulo
- Study Director: Lia Rita A Bittencourt, MD, PhD, Associacao Fundo de Incentivo a Psicofarmacologia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0985/08
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.